This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.
Robotics Stocks With Strong Potential for Long-Term Growth
by Vasundhara Sawalka
Robotics is poised for robust growth in the near term. Watch PATH, NVDA, AMD and SERV for potential market dominance across sectors.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
ISRG's Gross Margin Falls on Product Transition and Trade Pressures
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
by Indrajit Bandyopadhyay
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
by Zacks Equity Research
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
by Zacks Equity Research
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
Intuitive Surgical (ISRG) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Intuitive Surgical (ISRG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts
by Zacks Equity Research
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Intuitive Surgical (ISRG) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Intuitive Surgical (ISRG) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Intuitive Surgical, Inc. (ISRG) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +14.06% and +3.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Pre-Markets Marginally Higher on Q2 Earnings
by Zacks Equity Research
Pre-Markets Marginally Higher on Q2 Earnings.
Earnings Beats for GM, DHI, KO, etc. Lead Pre-Markets Slightly Higher
by Mark Vickery
We are devoid major economic reports ahead of today's open, but have plenty of quarterly earnings results.
ISRG vs. SYK: Which Robotic Surgery Stock Is the Stronger Buy Today?
by Indrajit Bandyopadhyay
Both are leaders in robotic-assisted surgery - Intuitive Surgical in soft tissue procedures and Stryker in orthopedic surgeries. Which company is a better bet now?
ISRG Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Zacks Equity Research
Intuitive Surgical's second-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
by Zacks Equity Research
Intuitive Surgical wins FDA nod for its Vessel Sealer Curved, boosting the da Vinci system's precision and multifunctional capabilities.
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
by Zacks Equity Research
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Unlocking Q2 Potential of Intuitive Surgical (ISRG): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Intuitive Surgical (ISRG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG?
by Indrajit Bandyopadhyay
Intuitive Surgical's global da Vinci growth faces resistance as hospital CapEx tightens abroad, testing leasing and utilization strategies.
Why Intuitive Surgical, Inc. (ISRG) Dipped More Than Broader Market Today
by Zacks Equity Research
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $512.06, denoting a -2.66% move from the preceding trading day.
3 AI-Driven Medical Device Stocks to Watch in 2025
by Sridatri Sarkar
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
by Indrajit Bandyopadhyay
Intuitive Surgical's installed base tops 10,000, but flat utilization growth raises questions about ROI and system productivity.
Intuitive Surgical, Inc. (ISRG) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $534.65, marking a -1.8% move from the previous day.